Radiotherapy Market Size, Share, Opportunities, And Trends By Therapy Type (External Beam Radiotherapy, Internal Beam Radiotherapy/Brachytherapy, Systemic Radiotherapy), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Head And Neck Cancer, Others), By End-User (Hospitals, Ambulatory Surgical Centres, Others), And By Geography - Forecasts From 2025 To 2030

Radiotherapy Market Size:

The Radiotherapy Market is expected to grow from USD 7.038 billion in 2025 to USD 8.997 billion in 2030, at a CAGR of 5.03%.

Radiotherapy Market Highlights:

• Radiotherapy market grows with rising cancer cases and technological advancements.
• North America leads, driven by hospitals and external beam radiotherapy.
• Asia Pacific expands rapidly, fueled by healthcare investments in China, India.
• High costs and professional shortages challenge accessibility in low-resource regions.

The Radiotherapy Market is a pivotal segment of the global healthcare industry, delivering targeted radiation treatments to eradicate cancerous cells while minimizing damage to healthy tissues. Radiotherapy, a cornerstone of cancer treatment, is used in over 50% of cancer cases worldwide, either as a primary therapy or in combination with surgery and chemotherapy. The market is driven by rising cancer prevalence, technological advancements, and increasing healthcare investments, the market is poised for significant growth.

The Radiotherapy Market is a vital component of global cancer care, driven by rising cancer prevalence, technological advancements, increasing healthcare investments, and aging populations. Despite challenges like high costs, side effects, and workforce shortages, the market is experiencing robust growth, supported by innovations in precision radiotherapy and expanding oncology infrastructure. The external beam radiotherapy, prostate cancer, and hospitals segments are critical, driven by the need for effective, accessible cancer treatments. Industry experts should focus on innovation, regulatory compliance, and regional healthcare trends to capitalize on the market’s growth potential.

Radiotherapy Market Overview:

Radiotherapy employs ionizing radiation to target and destroy malignant cells, offering a non-invasive or minimally invasive treatment option for various cancers. External beam radiotherapy (EBRT) delivers radiation from outside the body using linear accelerators, suitable for a wide range of cancers. Internal beam radiotherapy, or brachytherapy, involves placing radioactive sources inside or near the tumor, ideal for localized cancers like prostate and cervical. Systemic radiotherapy uses radioactive drugs, such as radioiodine, to target cancer cells throughout the body, often for thyroid cancer. Applications include prostate, breast, lung, and head and neck cancers, with other cancers like colorectal and brain tumors also treated. End-users primarily include hospitals, which handle complex cases, and ambulatory surgical centres for outpatient procedures. The market’s growth reflects the increasing global cancer burden and the demand for precise, effective treatments.

The Radiotherapy Market is set for sustained growth through 2030, driven by rising cancer incidence, technological advancements, and expanding healthcare infrastructure. The integration of AI and machine learning in radiotherapy planning will improve precision and efficiency, particularly in EBRT and brachytherapy. Asia Pacific will lead growth, fueled by China and India’s large patient populations and oncology investments. North America and Europe will maintain strong positions, driven by innovation and personalized medicine. Emerging applications in rare cancers and combination therapies will diversify the market. Addressing cost barriers and workforce shortages will be critical for equitable access, especially in low-resource regions. Industry experts should monitor technological trends, regulatory developments, and regional healthcare investments to leverage market opportunities.

Radiotherapy Market Growth Drivers:

Several factors are propelling the Radiotherapy Market:

• Rising Cancer Prevalence: Global cancer cases are increasing, with 19.3 million new diagnoses in 2020, projected to rise significantly by 2030, driving demand for radiotherapy (World Health Organization, 2020).
• Technological Advancements: Innovations in precision radiotherapy, such as IGRT and stereotactic body radiotherapy (SBRT), improve treatment outcomes. In March 2024, Varian launched the Halcyon 3.0 system, enhancing image-guided precision (Siemens Healthineers, 2024).
• Increasing Healthcare Investments: Governments and private sectors are boosting oncology infrastructure. In 2024, India allocated $1.2 billion to cancer care under the National Health Mission (Ministry of Health and Family Welfare, 2024).
• Aging Population: Older populations, more prone to cancer, increase radiotherapy demand. In 2024, 10% of the global population was over 65, with higher cancer incidence rates (United Nations, 2024).

Radiotherapy Market Restraints:

The market faces several challenges:

• High Equipment and Treatment Costs: Advanced radiotherapy systems, like proton therapy units, require significant investment, limiting access in low-resource settings.
• Side Effects and Safety Concerns: Radiation can cause side effects like fatigue and skin damage, deterring some patients from pursuing treatment.
• Shortage of Skilled Professionals: The complexity of radiotherapy requires trained oncologists and technicians, with a global shortage impacting service delivery.

Radiotherapy Market Geographical Analysis:

• North America

North America holds the largest share of the Radiotherapy Market, accounting for a significant portion of global revenue in 2025, driven by advanced healthcare infrastructure, high cancer incidence, and technological innovation. The U.S. leads with 1.9 million new cancer cases in 2024, with breast and prostate cancers being the most prevalent (American Cancer Society, 2024). The hospitals segment dominates, as 80% of radiotherapy treatments are administered in hospital-based oncology departments equipped with advanced linear accelerators. The external beam radiotherapy segment is prominent, with 70% of U.S. cancer patients receiving EBRT due to its versatility. Canada contributes through its universal healthcare system, with $500 million invested in cancer care in 2024 (Canadian Cancer Society, 2024). Mexico’s growing private healthcare sector supports market expansion, with 10% growth in oncology facilities in 2024 (Mexican Ministry of Health, 2024). The region’s growth is fueled by high healthcare spending, with U.S. healthcare expenditure reaching $4.5 trillion in 2024, and widespread adoption of precision radiotherapy systems.

The U.S. benefits from a robust ecosystem of innovation, with companies like Varian and Accuray developing cutting-edge solutions like SBRT and proton therapy. Regulatory support from the FDA, which approved 15 new radiotherapy devices in 2024, accelerates market growth (U.S. Food and Drug Administration, 2024). Canada’s focus on equitable access ensures radiotherapy availability in rural areas, while Mexico’s private hospitals cater to urban demand. North America’s leadership is reinforced by its research institutions, such as the National Cancer Institute, and collaborative clinical trials advancing radiotherapy techniques.

• Asia Pacific

Asia Pacific is the fastest-growing region, driven by rising cancer incidence, increasing healthcare investments, and expanding oncology infrastructure. China leads with 4.8 million new cancer cases in 2024, primarily lung and breast cancers, necessitating advanced radiotherapy solutions (National Cancer Center of China, 2024). India’s cancer burden grew by 8% in 2024, with $1.2 billion allocated to oncology under the National Health Mission (Ministry of Health and Family Welfare, 2024). The hospitals segment dominates, as 90% of radiotherapy treatments occur in public and private hospitals. The external beam radiotherapy segment is significant, with 65% of patients receiving EBRT due to its accessibility. Japan and South Korea contribute through advanced technology adoption, with Japan investing $1 billion in proton therapy centres in 2024 (Japanese Ministry of Health, 2024). The region’s growth is supported by government initiatives, such as China’s Healthy China 2030 plan, and rising private sector involvement.

China’s rapid expansion of radiotherapy facilities, with 1,200 new oncology centres planned by 2030, drives market growth. India’s focus on affordable cancer care, including subsidized EBRT in public hospitals, boosts accessibility. Japan’s leadership in precision radiotherapy, with systems like CyberKnife, supports high-quality treatment. South Korea’s investment in AI-integrated radiotherapy systems enhances treatment planning. Emerging markets like Thailand and Indonesia are expanding oncology services, with Thailand’s cancer care budget increasing by 15% in 2024 (Thai Ministry of Public Health, 2024). Asia Pacific’s growth is propelled by its large patient pool, improving healthcare infrastructure, and technological advancements.

• Europe

Europe holds a substantial market share, driven by advanced healthcare systems, regulatory support, and a focus on personalized medicine. Germany and the UK lead, with Germany reporting 500,000 new cancer cases in 2024, primarily breast and prostate cancers (German Cancer Research Center, 2024). The hospitals segment dominates, with 85% of radiotherapy treatments delivered in specialized oncology units. The external beam radiotherapy segment is prominent, with 75% of patients receiving EBRT due to its efficacy. France contributes through its national cancer plan, with €1.5 billion invested in oncology in 2024 (French Ministry of Health, 2024). The region’s growth is supported by EU funding, with €4 billion allocated to cancer research under Horizon Europe in 2024 (European Commission, 2024), and widespread adoption of advanced radiotherapy technologies like IGRT.

Germany’s leadership in proton therapy, with 10 operational centres in 2024, enhances treatment precision. The UK’s NHS Cancer Plan aims to increase radiotherapy access by 20% by 2030, driving market growth. France’s focus on reducing treatment side effects through SBRT supports patient outcomes. Collaborative research across Europe, such as the European Society for Radiotherapy and Oncology (ESTRO), advances clinical protocols. The region’s emphasis on sustainability and patient-centric care, coupled with regulatory frameworks like the EU Medical Device Regulation, ensures high standards in radiotherapy delivery.

Radiotherapy Market Key Segment Analysis:

• External Beam Radiotherapy

The external beam radiotherapy (EBRT) segment is the largest, driven by its versatility, non-invasive nature, and widespread adoption across cancer types. EBRT uses linear accelerators to deliver precise radiation doses, treating cancers like prostate, breast, and lung. In March 2024, Varian launched the Halcyon 3.0 system, enhancing image-guided precision and reducing treatment times (Siemens Healthineers, 2024). The segment’s dominance is fueled by demand from hospitals, with 70% of global radiotherapy treatments using EBRT in 2024. EBRT’s growth is supported by advancements like IGRT and SBRT, which improve targeting accuracy and minimize side effects. North America and Europe lead this segment, with the U.S. and Germany investing heavily in advanced linear accelerators.

EBRT’s ability to treat a wide range of cancers, from early-stage to metastatic, makes it a preferred modality. For instance, in prostate cancer, EBRT achieves 5-year survival rates of over 90% in localized cases (American Cancer Society, 2024). The integration of AI in treatment planning enhances dose optimization, reducing harm to healthy tissues. The segment’s growth is further driven by increasing cancer incidence and the expansion of radiotherapy facilities in Asia Pacific, where EBRT is the most accessible option due to its established infrastructure.

• Prostate Cancer Application

The prostate cancer application segment is significant, driven by high incidence rates and radiotherapy’s effectiveness as a primary or adjuvant treatment. Prostate cancer accounted for 1.4 million new cases globally in 2020, with numbers rising in 2024 (World Health Organization, 2020). Radiotherapy, particularly EBRT and brachytherapy, offers high cure rates, with 95% survival for early-stage cases (American Cancer Society, 2024). In April 2024, Elekta introduced the Harmony Pro, a linear accelerator optimized for prostate cancer treatment with enhanced precision (Elekta AB, 2024). The segment’s growth is supported by aging populations, with men over 65 at higher risk, and screening programs increasing early detection.

Prostate cancer’s prevalence in North America and Europe drives significant radiotherapy demand, with the U.S. reporting 250,000 new cases in 2024. Brachytherapy, used in 20% of cases, offers targeted treatment with minimal side effects, while EBRT is preferred for advanced stages. Asia Pacific is seeing rising demand due to improving healthcare access and awareness. The segment’s importance is underscored by ongoing research into hypofractionated radiotherapy, which reduces treatment duration while maintaining efficacy, enhancing patient convenience, and cost-effectiveness.

• Hospitals End-User

The hospitals segment dominates, accounting for the majority of radiotherapy treatments, driven by their advanced infrastructure and multidisciplinary oncology teams. Hospitals are equipped with high-end systems like linear accelerators and proton therapy units, handling complex cases across all cancer types. In 2024, 80% of global radiotherapy procedures were performed in hospitals, with North America and Europe leading due to their extensive oncology departments (World Health Organization, 2024). The segment’s growth is supported by increasing cancer incidence and government investments, such as the UK’s £500 million NHS cancer infrastructure fund in 2024 (UK Department of Health, 2024).

Hospitals offer comprehensive care, integrating radiotherapy with surgery, chemotherapy, and diagnostic services, making them the preferred setting for cancer treatment. The adoption of advanced technologies, like Varian’s Halcyon system, enhances treatment precision and patient throughput. In Asia Pacific, public hospitals are expanding radiotherapy capacity to address rising demand, while private hospitals in the Middle East cater to affluent patients. The segment’s dominance is reinforced by its ability to manage high patient volumes and complex cases, ensuring optimal outcomes.

Radiotherapy Market Key Developments:

• Varian Halcyon 3.0 System Launch: In March 2024, Varian launched the Halcyon 3.0 system, enhancing image-guided precision for EBRT (Siemens Healthineers, 2024).
• Elekta Harmony Pro Introduction: In April 2024, Elekta introduced the Harmony Pro linear accelerator, optimized for prostate cancer treatment (Elekta AB, 2024).
• Accuray CyberKnife S7 Upgrade: In January 2024, Accuray upgraded the CyberKnife S7 system, improving SBRT delivery for lung and head and neck cancers (Accuray Incorporated, 2024).
• India National Health Mission Investment: In 2024, India allocated $1.2 billion to cancer care, expanding radiotherapy facilities (Ministry of Health and Family Welfare, 2024).
• Japan Proton Therapy Investment: In 2024, Japan invested $1 billion in proton therapy centres, enhancing advanced radiotherapy access (Japanese Ministry of Health, 2024).
• EU Horizon Europe Funding: In 2024, the EU allocated €4 billion to cancer research, supporting radiotherapy advancements (European Commission, 2024).
• U.S. FDA Approvals: In 2024, the FDA approved 15 new radiotherapy devices, accelerating market innovation (U.S. Food and Drug Administration, 2024).

List of Top Radiotherapy Companies:

• Elekta AB
• Accuray Incorporated
• Ion Beam Applications (IBA)
• Isoray Medical, Inc.
• Canon Medical Systems Corporation

Radiotherapy Market Segmentation:

• By Therapy type
  • External Beam Radiotherapy
  • Internal Beam Radiotherapy/Brachytherapy
  • Systemic Radiotherapy
• By Application
  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Head And Neck Cancer
  • Others
• By End-user
  • Hospitals
  • Ambulatory Surgical Centres
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Others
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation

2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY
3.1. Research Highlights

4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. RADIOTHERAPY MARKET ANALYSIS, BY THERAPY TYPE
5.1. Introduction
5.2. External Beam Radiotherapy
5.3. Internal Beam Radiotherapy/Brachytherapy
5.4. Systemic Radiotherapy 

6. RADIOTHERAPY MARKET ANALYSIS, BY APPLICATIONS
6.1. Introduction
6.2. Prostate Cancer
6.3. Breast Cancer
6.4. Lung Cancer
6.5. Head And Neck Cancer
6.6. Others 

7. RADIOTHERAPY MARKET ANALYSIS, BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Ambulatory Surgical Centres
7.4. Others 

8. RADIOTHERAPY MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. UK
8.4.4. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILE
10.1. Elekta AB
10.2. Accuray Incorporated
10.3. Ion Beam Applications (IBA)
10.4. Isoray Medical, Inc.
10.5. Canon Medical Systems Corporation
10.6. Mirada Medical
10.7. Eckert & Ziegler
10.8. Siemens Healthineers
10.9. Varian Medical Systems, Inc
10.10. Mevion Medical Systems, Inc.

Elekta AB

Accuray Incorporated

Ion Beam Applications (IBA)

Isoray Medical, Inc.

Canon Medical Systems Corporation

Mirada Medical

Eckert & Ziegler

Siemens Healthineers

Varian Medical Systems, Inc

Mevion Medical Systems, Inc.